An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of Olaparib Following a Single Oral 300 mg Dose to Patients With Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment

Trial Profile

An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of Olaparib Following a Single Oral 300 mg Dose to Patients With Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Olaparib (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 24 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 18 Mar 2017 Results (n=67) assessing pharmacokinetics and safety of olaparib using patient data from NCT01894256 and NCT01894243 trials, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 31 Jan 2017 Planned End Date changed from 1 Jan 2018 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top